<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01924767</url>
  </required_header>
  <id_info>
    <org_study_id>1245.2</org_study_id>
    <secondary_id>2007-000654-32</secondary_id>
    <nct_id>NCT01924767</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 10773 Tablets</brief_title>
  <official_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 4 Multiple Rising Oral Doses (2.5 mg to 100 mg) of BI 10773 Tablets in Male and Female Type 2 Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To investigate safety, tolerability, pharmacokinetics and pharmacodynamics of BI 10773 with
      repeat dosing for eight days and the exploration of the pharmacokinetics and pharmacodynamics
      of BI 10773 after multiple dosing, including dose proportionality and assessment of steady
      state.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Clinically Relevant Findings in Physical Examination, Vital Signs and Clinical Laboratory Tests</measure>
    <time_frame>day 1 to day 21</time_frame>
    <description>Percentage of participants with clinically relevant findings in physical examination, vital signs and clinical laboratory tests. Relevant findings or worsenings of baseline conditions were reported as Adverse Events (cardiac disorders and investigations).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Clinically Relevant Findings in Electrocardiogram (ECG) Results</measure>
    <time_frame>day 1 to day 21</time_frame>
    <description>Percentage of participants with clinically relevant findings in electrocardiogram (ECG) results</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Micturition Frequency</measure>
    <time_frame>Baseline and Day 9</time_frame>
    <description>Micturition frequency is reported as change from pre-treatment to day 9 during the day, the night and total. Baseline is the mean of days 8-3 before drug administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of Tolerability by Investigator</measure>
    <time_frame>day 21</time_frame>
    <description>Tolerability will be assessed by the investigator according to the categories good, satisfactory, not satisfactory and bad.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of the Analyte in Plasma</measure>
    <time_frame>-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1.-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.</time_frame>
    <description>Maximum concentration of the analyte in plasma (Cmax) after first dose, Maximum, minimum (Cmin) and average (Cavg) concentration of the analyte in plasma at steady-state, Concentration of analyte in plasma at 24 h after administration of the 8th dose (at steady-state) (C24,8)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval (AUC)</measure>
    <time_frame>-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1.-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.</time_frame>
    <description>AUC0-∞: from 0 extrapolated to infinity after first dose AUCtau,1: over a uniform dosing interval tau after first dose AUCtau,ss: over a uniform dosing interval tau at steady-state AUCs were computed using the linear up/log down algorithm. If an analyte concentration was equal to or higher than the preceding concentration, the linear trapezoidal method was to be used. If the analyte concentration was smaller than the preceding concentration, the logarithmic method was to be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Concentration of the Analyte in Plasma</measure>
    <time_frame>-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1.-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.</time_frame>
    <description>Time from last dosing to maximum concentration of the analyte in plasma (tmax) after first dose and at steady-state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Rate Constant in Plasma</measure>
    <time_frame>-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.</time_frame>
    <description>Terminal rate constant in plasma after first dose and at steady-state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life and Mean Residence Time of the Analyte in Plasma</measure>
    <time_frame>-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.</time_frame>
    <description>Terminal half life of the analyte in plasma (t1/2) and mean residence time of the analyte in the body after single oral administration (MRTpo) after first dose and at steady-state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution During the Terminal Phase</measure>
    <time_frame>-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.</time_frame>
    <description>Apparent volume of distribution during the terminal phase (Vz/F) after first dose and at steady state. Apparent volume is defined as CL/F divided by the terminal rate constant in plasma (either after first dose or at steady-state).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of Analyte Eliminated in Urine</measure>
    <time_frame>0-2, 2-4, 4-6, 6-8, 8-12, 12-16, 16-24, 24-36, 36-48 hours (h) after dose on day 1 and 0-2, 2-4, 4-6, 6-8, 8-12, 12-16, 16-24, 24-36, 36-48 and 48-72 hours (h) after dose on day 9</time_frame>
    <description>Amount of analyte that is eliminated in urine after first dose and at steady state from the time interval 0 to 24 h (Ae0-24) and 0 to 48 h (Ae0-48)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction of Analyte Excreted Unchanged in Urine</measure>
    <time_frame>0-2, 2-4, 4-6, 6-8, 8-12, 12-16, 16-24, 24-36, 36-48 hours (h) after dose on day 1 and 0-2, 2-4, 4-6, 6-8, 8-12, 12-16, 16-24, 24-36, 36-48 and 48-72 hours (h) after dose on day 9</time_frame>
    <description>Fraction of analyte excreted unchanged in urine in the time interval 0 to 12 h (fe0-12) after first dose and at steady-state. The fraction excreted was calculated by dividing Ae0-12 by the Dose and multiply it with 100.
Fraction of analyte excreted unchanged in urine in the time interval 0 to 24 h (fe0-24) after first dose and at steady-state. The fraction excreted was calculated by dividing Ae0-24 by the Dose and multiply it with 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent and Renal Clearance of the Analyte in Plasma</measure>
    <time_frame>-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.</time_frame>
    <description>Apparent clearance of the analyte in plasma (CL/F) after first dose and at steady-state, Renal clearance of the analyte in plasma after extravascular administration (CLR) after first dose and at steady-state.
Apparent clearance after first dose is defined as the dose divided by AUC0-∞; apparent clearance at steady-state is defined as the dose divided by AUC0-tau at steady-state.
Renal clearance CLR(0-t) is defined as Ae0-t divided by AUC0-t.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Trough Fluctuation</measure>
    <time_frame>-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.</time_frame>
    <description>Peak trough fluctuation (PTF) is defined as the difference between Cmax and Cmin divided by Cavg and multiplied with 100% at steady-state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Linearity Index</measure>
    <time_frame>-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.</time_frame>
    <description>The linearity index is defined as AUC0-tau divided by AUC0-∞ both at steady state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Ratios</measure>
    <time_frame>-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.</time_frame>
    <description>Accumulation ratio based on Cmax (RA,Cmax) and Accumulated ratio based on AUC0-tau (RA,AUC) at steady-state.
Accumulation ratio for the respective doses were calculated using below mentioned equations:
RA,Cmax = Cmax,ss/Cmax
RA,AUC= AUCtau,ss/AUCtau</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 8 in Urinary Glucose Excretion</measure>
    <time_frame>-2-0 hours(h) before drug administration and 0-2, 2-4, 4-6, 6-8, 8-12,12-16 and 16-24 h after drug administration on day -2 and day 8</time_frame>
    <description>Change from baseline to day 8 in urinary glucose excretion. Baseline is defined as Day -2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Daily Glucose</measure>
    <time_frame>0:00, 2:00, 5:00, 7:00, 10:00, 12:00,13:30 and 24:00 hours(h) after drug administration on day -2 and -0.05, 2:30, 5:00, 7:00, 10:00, 12.00, 13:30 and 24:00 hours (h) after drug administration on day 8</time_frame>
    <description>Change from baseline to Day 8 in mean daily glucose. Baseline is defined as Day -2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Plasma Glucose</measure>
    <time_frame>-0:30 (Pre dose samples)</time_frame>
    <description>Percentage change from baseline to Day 8 in fasting plasma glucose. Baseline is defined as Day -2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Insulin</measure>
    <time_frame>0.0h, 2h, 5h, 7h, 10h, 12h on day -2 &amp; day 8</time_frame>
    <description>Serum insulin measured for on day -2 and day 8 for AUEC0-5 and AUEC0-12. AUEC0-5: The area under the effect concentration-time curve over the time interval 0 to 5.
AUEC0-12: The area under the effect concentration-time curve over the time interval 0 to 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Insulin</measure>
    <time_frame>0.0h, 2h, 5h, 7h, 10h, 12h on day -2 &amp; day 8</time_frame>
    <description>Serum insulin measured for on day -2 and day 8 for Emax0-5, Emax0-12, Emin0-5 and Emin0-12.
Emax: Maximum effect (maximum measured concentration of glucose or insulin in plasma) &amp; Emin: Minimum effect (minimum measured concentration of glucose or insulin in plasma)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>BI 10773 (dose group 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multiple doses as tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 10773 (dose group 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multiple doses as tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 10773 (dose group 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multiple doses as tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 10773 (dose group 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multiple doses as tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773 Placebo</intervention_name>
    <description>po taken fasting with 240 mL water</description>
    <arm_group_label>BI 10773 (dose group 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>po taken fasting with 240 mL water</description>
    <arm_group_label>BI 10773 (dose group 4)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773 Placebo</intervention_name>
    <description>po taken fasting with 240 mL water</description>
    <arm_group_label>BI 10773 (dose group 3)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>po taken fasting with 240 mL water</description>
    <arm_group_label>BI 10773 (dose group 3)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773 Placebo</intervention_name>
    <description>po taken fasting with 240 mL water</description>
    <arm_group_label>BI 10773 (dose group 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773 Placebo</intervention_name>
    <description>po taken fasting with 240 mL water</description>
    <arm_group_label>BI 10773 (dose group 4)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>po taken fasting with 240 mL water</description>
    <arm_group_label>BI 10773 (dose group 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>po taken fasting with 240 mL water</description>
    <arm_group_label>BI 10773 (dose group 1)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Male and postmenopausal or hysterectomised female patients with proven diagnosis of
             type 2 diabetes mellitus treated with diet and exercise only or on a maximum of two
             oral antidiabetic agents except thiazolidindiones with at least one agent taken at 50%
             of its maximum dose or less.

          2. Glycosylated haemoglobin A1 (HbA1c) £ 8.5 % at screening.

          3. Age &gt;21 and Age &lt;70 years (male and hysterectomised female patients) Age &gt;60 and Age
             &lt;70 years (postmenopausal female patients)

          4. Body Mass Index (BMI) &gt;18.5 and &lt;40 kg/m2

          5. Signed and dated written informed consent prior to admission to the study in
             accordance with GCP and the local legislation

        Exclusion criteria:

          1. Antidiabetic treatment with insulin or glitazones or with more than one oral
             hypoglycaemic agent (except if 2 agents and at least one of them not taken at more
             than 50% of its maximum dose)

          2. Fasted blood glucose &gt; 240 mg/dl (&gt;13.3 mmol/L) on two consecutive days during
             washout.

          3. Glycosylated haemoglobin A1 (HbA1c) &gt;8.5% at screening

          4. Clinically relevant concomitant diseases other than type 2 diabetes, hyperlipidaemia
             and medically treated hypertension, such as:

               -  Any late stage complication of diabetes (e.g. retinopathy, polyneuropathy,
                  vegetative disorders, diabetic foot)

               -  Renal insufficiency (calculated creatinine clearance &lt; 80 ml/min/1.73m²)

               -  Cardiac insufficiency NYHA II-IV, myocardial infarction, other known
                  cardiovascular diseases including hypertension &gt; 160/95mmHg (measured at training
                  visit and each of the timepoints of Day -1), stroke and TIA (Transistoric
                  ischaemic attack)

               -  Neurological disorders (such as epilepsy) or psychiatric disorders

               -  Acute or relevant chronic infections (e.g. HIV, repeated urogenital infections)

               -  Any gastrointestinal, hepatic, respiratory, endocrine or immunological disorder

          5. History of relevant allergy/hypersensitivity (including allergy to drug or its
             excipients)

          6. A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a
             QTc interval &gt;450 ms)

          7. A history of additional risk factors for TdP (torsade des pointes) (e.g., heart
             failure, hypokalemia, family history of sudden death before the age of 50)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1245.2.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Neuss</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2013</study_first_submitted>
  <study_first_submitted_qc>August 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2013</study_first_posted>
  <results_first_submitted>May 16, 2014</results_first_submitted>
  <results_first_submitted_qc>July 3, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 4, 2014</results_first_posted>
  <last_update_submitted>July 3, 2014</last_update_submitted>
  <last_update_submitted_qc>July 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This Phase I trial was randomised, double-blind, and placebo-controlled within dose groups. It was to be performed in 48 female and male patients with type 2 diabetes in 4 sequential groups of 12 patients each. Within each dose group, 9 patients were to receive active drug and 3 were to receive placebo.</recruitment_details>
      <pre_assignment_details>14 days wash-out of previous antidiabetic therapy followed by 8 days of once daily dosing at each dose level.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Patients were treated with matching placebo as tablet once daily (qd) in the morning.</description>
        </group>
        <group group_id="P2">
          <title>Empagliflozin 2.5 mg qd</title>
          <description>Patients were treated with 2.5 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
        </group>
        <group group_id="P3">
          <title>Empagliflozin 10 mg qd</title>
          <description>Patients were treated with 10 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
        </group>
        <group group_id="P4">
          <title>Empagliflozin 25 mg qd</title>
          <description>Patients were treated with 25 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
        </group>
        <group group_id="P5">
          <title>Empagliflozin 100 mg qd</title>
          <description>Patients were treated with 100 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated set includes all patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Patients were treated with matching placebo as tablet once daily in the morning.</description>
        </group>
        <group group_id="B2">
          <title>Empagliflozin 2.5 mg qd</title>
          <description>Patients were treated with 2.5 mg Empagliflozin as tablet once daily in the morning.</description>
        </group>
        <group group_id="B3">
          <title>Empagliflozin 10 mg qd</title>
          <description>Patients were treated with 10 mg Empagliflozin as tablet once daily in the morning.</description>
        </group>
        <group group_id="B4">
          <title>Empagliflozin 25 mg qd</title>
          <description>Patients were treated with 25 mg Empagliflozin as tablet once daily in the morning.</description>
        </group>
        <group group_id="B5">
          <title>Empagliflozin 100 mg qd</title>
          <description>Patients were treated with 100 mg Empagliflozin as tablet once daily in the morning.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="9"/>
            <count group_id="B5" value="9"/>
            <count group_id="B6" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.9" spread="6.4"/>
                    <measurement group_id="B2" value="53.9" spread="10.9"/>
                    <measurement group_id="B3" value="51.8" spread="10.7"/>
                    <measurement group_id="B4" value="58.9" spread="8.8"/>
                    <measurement group_id="B5" value="60.3" spread="5.6"/>
                    <measurement group_id="B6" value="56.9" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Clinically Relevant Findings in Physical Examination, Vital Signs and Clinical Laboratory Tests</title>
        <description>Percentage of participants with clinically relevant findings in physical examination, vital signs and clinical laboratory tests. Relevant findings or worsenings of baseline conditions were reported as Adverse Events (cardiac disorders and investigations).</description>
        <time_frame>day 1 to day 21</time_frame>
        <population>Treated set.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were treated with matching placebo as tablet once daily in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 2.5 mg qd</title>
            <description>Patients were treated with 2.5 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 10 mg qd</title>
            <description>Patients were treated with 10 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Empagliflozin 25 mg qd</title>
            <description>Patients were treated with 25 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Empagliflozin 100 mg qd</title>
            <description>Patients were treated with 100 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clinically Relevant Findings in Physical Examination, Vital Signs and Clinical Laboratory Tests</title>
          <description>Percentage of participants with clinically relevant findings in physical examination, vital signs and clinical laboratory tests. Relevant findings or worsenings of baseline conditions were reported as Adverse Events (cardiac disorders and investigations).</description>
          <population>Treated set.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cardiac disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Investigations: Hepatic enzyme increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Clinically Relevant Findings in Electrocardiogram (ECG) Results</title>
        <description>Percentage of participants with clinically relevant findings in electrocardiogram (ECG) results</description>
        <time_frame>day 1 to day 21</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were treated with matching placebo as tablet once daily in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 2.5 mg qd</title>
            <description>Patients were treated with 2.5 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 10 mg qd</title>
            <description>Patients were treated with 10 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Empagliflozin 25 mg qd</title>
            <description>Patients were treated with 25 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Empagliflozin 100 mg qd</title>
            <description>Patients were treated with 100 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clinically Relevant Findings in Electrocardiogram (ECG) Results</title>
          <description>Percentage of participants with clinically relevant findings in electrocardiogram (ECG) results</description>
          <population>Treated set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clinically relevant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinically irrelevant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                    <measurement group_id="O3" value="100.0"/>
                    <measurement group_id="O4" value="100.0"/>
                    <measurement group_id="O5" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Micturition Frequency</title>
        <description>Micturition frequency is reported as change from pre-treatment to day 9 during the day, the night and total. Baseline is the mean of days 8-3 before drug administration.</description>
        <time_frame>Baseline and Day 9</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were treated with matching placebo as tablet once daily in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 2.5 mg qd</title>
            <description>Patients were treated with 2.5 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 10 mg qd</title>
            <description>Patients were treated with 10 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Empagliflozin 25 mg qd</title>
            <description>Patients were treated with 25 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Empagliflozin 100 mg qd</title>
            <description>Patients were treated with 100 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Micturition Frequency</title>
          <description>Micturition frequency is reported as change from pre-treatment to day 9 during the day, the night and total. Baseline is the mean of days 8-3 before drug administration.</description>
          <population>Treated set</population>
          <units>frequency of micturition</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Micturition day frequency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="1.8"/>
                    <measurement group_id="O2" value="2.6" spread="2.1"/>
                    <measurement group_id="O3" value="5.0" spread="1.6"/>
                    <measurement group_id="O4" value="3.9" spread="1.5"/>
                    <measurement group_id="O5" value="4.4" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Micturition night frequency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="1.6"/>
                    <measurement group_id="O2" value="0.2" spread="1.2"/>
                    <measurement group_id="O3" value="0.5" spread="0.5"/>
                    <measurement group_id="O4" value="0.6" spread="1.6"/>
                    <measurement group_id="O5" value="0.7" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Micturition total frequency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="2.1"/>
                    <measurement group_id="O2" value="2.8" spread="2.6"/>
                    <measurement group_id="O3" value="5.5" spread="1.5"/>
                    <measurement group_id="O4" value="4.4" spread="2.4"/>
                    <measurement group_id="O5" value="5.1" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Assessment of Tolerability by Investigator</title>
        <description>Tolerability will be assessed by the investigator according to the categories good, satisfactory, not satisfactory and bad.</description>
        <time_frame>day 21</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were treated with matching placebo as tablet once daily in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 2.5 mg qd</title>
            <description>Patients were treated with 2.5 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 10 mg qd</title>
            <description>Patients were treated with 10 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Empagliflozin 25 mg qd</title>
            <description>Patients were treated with 25 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Empagliflozin 100 mg qd</title>
            <description>Patients were treated with 100 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Tolerability by Investigator</title>
          <description>Tolerability will be assessed by the investigator according to the categories good, satisfactory, not satisfactory and bad.</description>
          <population>Treated set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.7"/>
                    <measurement group_id="O2" value="100.0"/>
                    <measurement group_id="O3" value="100.0"/>
                    <measurement group_id="O4" value="100.0"/>
                    <measurement group_id="O5" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfactory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not satisfactory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bad</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration of the Analyte in Plasma</title>
        <description>Maximum concentration of the analyte in plasma (Cmax) after first dose, Maximum, minimum (Cmin) and average (Cavg) concentration of the analyte in plasma at steady-state, Concentration of analyte in plasma at 24 h after administration of the 8th dose (at steady-state) (C24,8)</description>
        <time_frame>-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1.-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.</time_frame>
        <population>Pharmacokinetic set (PK set) contains of all patients who received study medication and have evaluable pharmacokinetic parameter data. The PK set will not contain placebo patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin 2.5 mg qd</title>
            <description>Patients were treated with 2.5 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10 mg qd</title>
            <description>Patients were treated with 10 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 25 mg qd</title>
            <description>Patients were treated with 25 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Empagliflozin 100 mg qd</title>
            <description>Patients were treated with 100 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of the Analyte in Plasma</title>
          <description>Maximum concentration of the analyte in plasma (Cmax) after first dose, Maximum, minimum (Cmin) and average (Cavg) concentration of the analyte in plasma at steady-state, Concentration of analyte in plasma at 24 h after administration of the 8th dose (at steady-state) (C24,8)</description>
          <population>Pharmacokinetic set (PK set) contains of all patients who received study medication and have evaluable pharmacokinetic parameter data. The PK set will not contain placebo patients.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax after first dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.3" spread="20.5"/>
                    <measurement group_id="O2" value="240" spread="21.2"/>
                    <measurement group_id="O3" value="592" spread="23.7"/>
                    <measurement group_id="O4" value="2670" spread="26.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax at steady-state (N=9,8,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.6" spread="26.7"/>
                    <measurement group_id="O2" value="272" spread="30.1"/>
                    <measurement group_id="O3" value="622" spread="17.4"/>
                    <measurement group_id="O4" value="2700" spread="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmin at steady-state (N=9,8,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.41" spread="36.9"/>
                    <measurement group_id="O2" value="23.5" spread="31.5"/>
                    <measurement group_id="O3" value="47.1" spread="35.3"/>
                    <measurement group_id="O4" value="243" spread="32.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cavg at steady-state (N=9,8,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.2" spread="24.3"/>
                    <measurement group_id="O2" value="83.5" spread="17.4"/>
                    <measurement group_id="O3" value="204" spread="21.5"/>
                    <measurement group_id="O4" value="922" spread="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C24,8 (N=9,8,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.55" spread="36.8"/>
                    <measurement group_id="O2" value="23.8" spread="31.7"/>
                    <measurement group_id="O3" value="47.2" spread="35.2"/>
                    <measurement group_id="O4" value="249" spread="27.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This was non-confirmatory testing, dose proportionality of dose from 2.5mg to 100mg for Cmax (single dose) was analysed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Mean of ratio</param_type>
            <param_value>43.661</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>27.520</ci_lower_limit>
            <ci_upper_limit>69.269</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This was non-confirmatory testing, dose proportionality of dose from 2.5mg to 100mg for Cmax,ss (Multiple dose) was analysed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Mean of ratio</param_type>
            <param_value>31.234</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.193</ci_lower_limit>
            <ci_upper_limit>80.011</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval (AUC)</title>
        <description>AUC0-∞: from 0 extrapolated to infinity after first dose AUCtau,1: over a uniform dosing interval tau after first dose AUCtau,ss: over a uniform dosing interval tau at steady-state AUCs were computed using the linear up/log down algorithm. If an analyte concentration was equal to or higher than the preceding concentration, the linear trapezoidal method was to be used. If the analyte concentration was smaller than the preceding concentration, the logarithmic method was to be used.</description>
        <time_frame>-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1.-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.</time_frame>
        <population>PK set</population>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin 2.5 mg qd</title>
            <description>Patients were treated with 2.5 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10 mg qd</title>
            <description>Patients were treated with 10 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 25 mg qd</title>
            <description>Patients were treated with 25 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Empagliflozin 100 mg qd</title>
            <description>Patients were treated with 100 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval (AUC)</title>
          <description>AUC0-∞: from 0 extrapolated to infinity after first dose AUCtau,1: over a uniform dosing interval tau after first dose AUCtau,ss: over a uniform dosing interval tau at steady-state AUCs were computed using the linear up/log down algorithm. If an analyte concentration was equal to or higher than the preceding concentration, the linear trapezoidal method was to be used. If the analyte concentration was smaller than the preceding concentration, the logarithmic method was to be used.</description>
          <population>PK set</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC0-∞ after first dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="468" spread="19.6"/>
                    <measurement group_id="O2" value="1890" spread="14.7"/>
                    <measurement group_id="O3" value="4780" spread="23.7"/>
                    <measurement group_id="O4" value="23300" spread="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC0-24 after first dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="397" spread="17.6"/>
                    <measurement group_id="O2" value="1620" spread="13.5"/>
                    <measurement group_id="O3" value="4200" spread="23.6"/>
                    <measurement group_id="O4" value="19700" spread="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC0-tau at steady state (N=9,8,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="460" spread="24.3"/>
                    <measurement group_id="O2" value="2000" spread="17.4"/>
                    <measurement group_id="O3" value="4890" spread="21.5"/>
                    <measurement group_id="O4" value="22100" spread="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This was non-confirmatory testing, dose proportionality of dose from 2.5mg to 100mg for AUC (0-infinity, single dose) was analysed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric mean of ratio</param_type>
            <param_value>49.707</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>33.490</ci_lower_limit>
            <ci_upper_limit>73.776</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This was non confirmatory testing, dose proportionality of dose from 2.5mg to 100mg for AUC (0-infinity, at steady state, day 9) was analysed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric mean of ratio</param_type>
            <param_value>37.632</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>15.429</ci_lower_limit>
            <ci_upper_limit>91.789</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Concentration of the Analyte in Plasma</title>
        <description>Time from last dosing to maximum concentration of the analyte in plasma (tmax) after first dose and at steady-state</description>
        <time_frame>-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1.-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.</time_frame>
        <population>PK set</population>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin 2.5 mg qd</title>
            <description>Patients were treated with 2.5 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10 mg qd</title>
            <description>Patients were treated with 10 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 25 mg qd</title>
            <description>Patients were treated with 25 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Empagliflozin 100 mg qd</title>
            <description>Patients were treated with 100 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Concentration of the Analyte in Plasma</title>
          <description>Time from last dosing to maximum concentration of the analyte in plasma (tmax) after first dose and at steady-state</description>
          <population>PK set</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>tmax after first dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="27.5" lower_limit="0.667" upper_limit="1.50"/>
                    <measurement group_id="O2" value="1.50" spread="18.2" lower_limit="0.983" upper_limit="2.00"/>
                    <measurement group_id="O3" value="1.50" spread="38.5" lower_limit="0.983" upper_limit="4.00"/>
                    <measurement group_id="O4" value="3.00" spread="77.8" lower_limit="0.983" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>tmax at steady-state (N=9,8,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="27.4" lower_limit="0.983" upper_limit="2.00"/>
                    <measurement group_id="O2" value="1.50" spread="24.3" lower_limit="0.983" upper_limit="2.00"/>
                    <measurement group_id="O3" value="2.00" spread="62.6" lower_limit="0.667" upper_limit="4.20"/>
                    <measurement group_id="O4" value="1.50" spread="62.3" lower_limit="0.983" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Rate Constant in Plasma</title>
        <description>Terminal rate constant in plasma after first dose and at steady-state</description>
        <time_frame>-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.</time_frame>
        <population>PK set</population>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin 2.5 mg qd</title>
            <description>Patients were treated with 2.5 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10 mg qd</title>
            <description>Patients were treated with 10 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 25 mg qd</title>
            <description>Patients were treated with 25 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Empagliflozin 100 mg qd</title>
            <description>Patients were treated with 100 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Rate Constant in Plasma</title>
          <description>Terminal rate constant in plasma after first dose and at steady-state</description>
          <population>PK set</population>
          <units>1/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Terminal rate after first dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0618" spread="22.4"/>
                    <measurement group_id="O2" value="0.0586" spread="11.5"/>
                    <measurement group_id="O3" value="0.0654" spread="19.9"/>
                    <measurement group_id="O4" value="0.0527" spread="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Terminal rate at steady-state (N=9,8,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0686" spread="18.5"/>
                    <measurement group_id="O2" value="0.0491" spread="17.5"/>
                    <measurement group_id="O3" value="0.0658" spread="18.8"/>
                    <measurement group_id="O4" value="0.0409" spread="48.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Half-life and Mean Residence Time of the Analyte in Plasma</title>
        <description>Terminal half life of the analyte in plasma (t1/2) and mean residence time of the analyte in the body after single oral administration (MRTpo) after first dose and at steady-state.</description>
        <time_frame>-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.</time_frame>
        <population>PK Set</population>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin 2.5 mg qd</title>
            <description>Patients were treated with 2.5 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10 mg qd</title>
            <description>Patients were treated with 10 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 25 mg qd</title>
            <description>Patients were treated with 25 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Empagliflozin 100 mg qd</title>
            <description>Patients were treated with 100 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Half-life and Mean Residence Time of the Analyte in Plasma</title>
          <description>Terminal half life of the analyte in plasma (t1/2) and mean residence time of the analyte in the body after single oral administration (MRTpo) after first dose and at steady-state.</description>
          <population>PK Set</population>
          <units>h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>t1/2 after first dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" spread="22.4"/>
                    <measurement group_id="O2" value="11.8" spread="11.5"/>
                    <measurement group_id="O3" value="10.6" spread="19.9"/>
                    <measurement group_id="O4" value="13.2" spread="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t1/2 at steady state (N=9,8,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" spread="18.5"/>
                    <measurement group_id="O2" value="14.1" spread="17.5"/>
                    <measurement group_id="O3" value="10.5" spread="18.8"/>
                    <measurement group_id="O4" value="17.0" spread="48.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MRT po after first dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" spread="12.4"/>
                    <measurement group_id="O2" value="12.1" spread="19.1"/>
                    <measurement group_id="O3" value="11.0" spread="13.5"/>
                    <measurement group_id="O4" value="12.7" spread="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MRT po at steady-state (9,8,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7" spread="14.2"/>
                    <measurement group_id="O2" value="13.5" spread="22.7"/>
                    <measurement group_id="O3" value="11.2" spread="13.7"/>
                    <measurement group_id="O4" value="14.6" spread="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution During the Terminal Phase</title>
        <description>Apparent volume of distribution during the terminal phase (Vz/F) after first dose and at steady state. Apparent volume is defined as CL/F divided by the terminal rate constant in plasma (either after first dose or at steady-state).</description>
        <time_frame>-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.</time_frame>
        <population>PK set</population>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin 2.5 mg qd</title>
            <description>Patients were treated with 2.5 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10 mg qd</title>
            <description>Patients were treated with 10 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 25 mg qd</title>
            <description>Patients were treated with 25 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Empagliflozin 100 mg qd</title>
            <description>Patients were treated with 100 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution During the Terminal Phase</title>
          <description>Apparent volume of distribution during the terminal phase (Vz/F) after first dose and at steady state. Apparent volume is defined as CL/F divided by the terminal rate constant in plasma (either after first dose or at steady-state).</description>
          <population>PK set</population>
          <units>L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vz/F after first dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="192" spread="27.2"/>
                    <measurement group_id="O2" value="200" spread="19.5"/>
                    <measurement group_id="O3" value="177" spread="27.9"/>
                    <measurement group_id="O4" value="181" spread="35.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vz/F at steady state (N=9,8,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176" spread="25.0"/>
                    <measurement group_id="O2" value="225" spread="25.9"/>
                    <measurement group_id="O3" value="172" spread="21.7"/>
                    <measurement group_id="O4" value="245" spread="56.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amount of Analyte Eliminated in Urine</title>
        <description>Amount of analyte that is eliminated in urine after first dose and at steady state from the time interval 0 to 24 h (Ae0-24) and 0 to 48 h (Ae0-48)</description>
        <time_frame>0-2, 2-4, 4-6, 6-8, 8-12, 12-16, 16-24, 24-36, 36-48 hours (h) after dose on day 1 and 0-2, 2-4, 4-6, 6-8, 8-12, 12-16, 16-24, 24-36, 36-48 and 48-72 hours (h) after dose on day 9</time_frame>
        <population>PK set</population>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin 2.5 mg qd</title>
            <description>Patients were treated with 2.5 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10 mg qd</title>
            <description>Patients were treated with 10 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 25 mg qd</title>
            <description>Patients were treated with 25 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Empagliflozin 100 mg qd</title>
            <description>Patients were treated with 100 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Analyte Eliminated in Urine</title>
          <description>Amount of analyte that is eliminated in urine after first dose and at steady state from the time interval 0 to 24 h (Ae0-24) and 0 to 48 h (Ae0-48)</description>
          <population>PK set</population>
          <units>nmol</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ae0-48 after first dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="706" spread="24.7"/>
                    <measurement group_id="O2" value="2570" spread="42.2"/>
                    <measurement group_id="O3" value="5250" spread="52.0"/>
                    <measurement group_id="O4" value="18500" spread="32.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ae0-48 at steady-state (N=9,8,8,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="941" spread="32.1"/>
                    <measurement group_id="O2" value="4530" spread="23.5"/>
                    <measurement group_id="O3" value="8450" spread="42.7"/>
                    <measurement group_id="O4" value="22400" spread="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ae0-24 after first dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="613" spread="26.9"/>
                    <measurement group_id="O2" value="2250" spread="42.7"/>
                    <measurement group_id="O3" value="4770" spread="54.6"/>
                    <measurement group_id="O4" value="16600" spread="34.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ae0-24 at steady-state (N=9,8,8,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="820" spread="33.9"/>
                    <measurement group_id="O2" value="4040" spread="26.7"/>
                    <measurement group_id="O3" value="7520" spread="43.6"/>
                    <measurement group_id="O4" value="19300" spread="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fraction of Analyte Excreted Unchanged in Urine</title>
        <description>Fraction of analyte excreted unchanged in urine in the time interval 0 to 12 h (fe0-12) after first dose and at steady-state. The fraction excreted was calculated by dividing Ae0-12 by the Dose and multiply it with 100.
Fraction of analyte excreted unchanged in urine in the time interval 0 to 24 h (fe0-24) after first dose and at steady-state. The fraction excreted was calculated by dividing Ae0-24 by the Dose and multiply it with 100.</description>
        <time_frame>0-2, 2-4, 4-6, 6-8, 8-12, 12-16, 16-24, 24-36, 36-48 hours (h) after dose on day 1 and 0-2, 2-4, 4-6, 6-8, 8-12, 12-16, 16-24, 24-36, 36-48 and 48-72 hours (h) after dose on day 9</time_frame>
        <population>PK set</population>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin 2.5 mg qd</title>
            <description>Patients were treated with 2.5 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10 mg qd</title>
            <description>Patients were treated with 10 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 25 mg qd</title>
            <description>Patients were treated with 25 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Empagliflozin 100 mg qd</title>
            <description>Patients were treated with 100 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Fraction of Analyte Excreted Unchanged in Urine</title>
          <description>Fraction of analyte excreted unchanged in urine in the time interval 0 to 12 h (fe0-12) after first dose and at steady-state. The fraction excreted was calculated by dividing Ae0-12 by the Dose and multiply it with 100.
Fraction of analyte excreted unchanged in urine in the time interval 0 to 24 h (fe0-24) after first dose and at steady-state. The fraction excreted was calculated by dividing Ae0-24 by the Dose and multiply it with 100.</description>
          <population>PK set</population>
          <units>percent of analyte</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>fe0-12 after first dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.50" spread="31.9"/>
                    <measurement group_id="O2" value="8.43" spread="39.8"/>
                    <measurement group_id="O3" value="6.30" spread="78.2"/>
                    <measurement group_id="O4" value="6.17" spread="37.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>fe0-12 at steady-state (N=9,8,8,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" spread="47.0"/>
                    <measurement group_id="O2" value="14.7" spread="26.5"/>
                    <measurement group_id="O3" value="9.22" spread="54.0"/>
                    <measurement group_id="O4" value="6.68" spread="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>fe0-24 after first dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" spread="26.9"/>
                    <measurement group_id="O2" value="10.1" spread="42.7"/>
                    <measurement group_id="O3" value="7.38" spread="73.0"/>
                    <measurement group_id="O4" value="7.48" spread="34.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>fe0-24 at steady-state (N=9,8,8,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8" spread="33.9"/>
                    <measurement group_id="O2" value="18.2" spread="26.7"/>
                    <measurement group_id="O3" value="11.4" spread="53.6"/>
                    <measurement group_id="O4" value="8.71" spread="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent and Renal Clearance of the Analyte in Plasma</title>
        <description>Apparent clearance of the analyte in plasma (CL/F) after first dose and at steady-state, Renal clearance of the analyte in plasma after extravascular administration (CLR) after first dose and at steady-state.
Apparent clearance after first dose is defined as the dose divided by AUC0-∞; apparent clearance at steady-state is defined as the dose divided by AUC0-tau at steady-state.
Renal clearance CLR(0-t) is defined as Ae0-t divided by AUC0-t.</description>
        <time_frame>-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.</time_frame>
        <population>PK set</population>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin 2.5 mg qd</title>
            <description>Patients were treated with 2.5 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10 mg qd</title>
            <description>Patients were treated with 10 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 25 mg qd</title>
            <description>Patients were treated with 25 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Empagliflozin 100 mg qd</title>
            <description>Patients were treated with 100 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent and Renal Clearance of the Analyte in Plasma</title>
          <description>Apparent clearance of the analyte in plasma (CL/F) after first dose and at steady-state, Renal clearance of the analyte in plasma after extravascular administration (CLR) after first dose and at steady-state.
Apparent clearance after first dose is defined as the dose divided by AUC0-∞; apparent clearance at steady-state is defined as the dose divided by AUC0-tau at steady-state.
Renal clearance CLR(0-t) is defined as Ae0-t divided by AUC0-t.</description>
          <population>PK set</population>
          <units>mL/min</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CL/F after first dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198" spread="19.6"/>
                    <measurement group_id="O2" value="195" spread="14.7"/>
                    <measurement group_id="O3" value="193" spread="23.7"/>
                    <measurement group_id="O4" value="159" spread="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CL/F at steady-state (N=9,8,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="201" spread="24.3"/>
                    <measurement group_id="O2" value="184" spread="17.4"/>
                    <measurement group_id="O3" value="189" spread="21.5"/>
                    <measurement group_id="O4" value="167" spread="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CLR (0-48h) after first dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.7" spread="42.9"/>
                    <measurement group_id="O2" value="23.5" spread="33.0"/>
                    <measurement group_id="O3" value="18.8" spread="53.1"/>
                    <measurement group_id="O4" value="13.9" spread="44.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CLR (0-24h) at steady-state (N=9,8,8,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.7" spread="52.0"/>
                    <measurement group_id="O2" value="33.6" spread="24.9"/>
                    <measurement group_id="O3" value="21.7" spread="47.1"/>
                    <measurement group_id="O4" value="22.2" spread="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Trough Fluctuation</title>
        <description>Peak trough fluctuation (PTF) is defined as the difference between Cmax and Cmin divided by Cavg and multiplied with 100% at steady-state</description>
        <time_frame>-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.</time_frame>
        <population>PK set</population>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin 2.5 mg qd</title>
            <description>Patients were treated with 2.5 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10 mg qd</title>
            <description>Patients were treated with 10 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 25 mg qd</title>
            <description>Patients were treated with 25 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Empagliflozin 100 mg qd</title>
            <description>Patients were treated with 100 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Trough Fluctuation</title>
          <description>Peak trough fluctuation (PTF) is defined as the difference between Cmax and Cmin divided by Cavg and multiplied with 100% at steady-state</description>
          <population>PK set</population>
          <units>PTF(%) of Empagliflozin</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="323" spread="20.6"/>
                    <measurement group_id="O2" value="294" spread="28.4"/>
                    <measurement group_id="O3" value="281" spread="26.4"/>
                    <measurement group_id="O4" value="265" spread="31.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Linearity Index</title>
        <description>The linearity index is defined as AUC0-tau divided by AUC0-∞ both at steady state.</description>
        <time_frame>-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.</time_frame>
        <population>PK set</population>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin 2.5 mg qd</title>
            <description>Patients were treated with 2.5 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10 mg qd</title>
            <description>Patients were treated with 10 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 25 mg qd</title>
            <description>Patients were treated with 25 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Empagliflozin 100 mg qd</title>
            <description>Patients were treated with 100 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Linearity Index</title>
          <description>The linearity index is defined as AUC0-tau divided by AUC0-∞ both at steady state.</description>
          <population>PK set</population>
          <units>Fraction</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.983" spread="8.42"/>
                    <measurement group_id="O2" value="1.05" spread="2.39"/>
                    <measurement group_id="O3" value="1.02" spread="11.4"/>
                    <measurement group_id="O4" value="0.962" spread="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Accumulation Ratios</title>
        <description>Accumulation ratio based on Cmax (RA,Cmax) and Accumulated ratio based on AUC0-tau (RA,AUC) at steady-state.
Accumulation ratio for the respective doses were calculated using below mentioned equations:
RA,Cmax = Cmax,ss/Cmax
RA,AUC= AUCtau,ss/AUCtau</description>
        <time_frame>-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.</time_frame>
        <population>PK set</population>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin 2.5 mg qd</title>
            <description>Patients were treated with 2.5 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10 mg qd</title>
            <description>Patients were treated with 10 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 25 mg qd</title>
            <description>Patients were treated with 25 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Empagliflozin 100 mg qd</title>
            <description>Patients were treated with 100 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Accumulation Ratios</title>
          <description>Accumulation ratio based on Cmax (RA,Cmax) and Accumulated ratio based on AUC0-tau (RA,AUC) at steady-state.
Accumulation ratio for the respective doses were calculated using below mentioned equations:
RA,Cmax = Cmax,ss/Cmax
RA,AUC= AUCtau,ss/AUCtau</description>
          <population>PK set</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Accumulation ratio based on Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" spread="27.0"/>
                    <measurement group_id="O2" value="1.13" spread="20.9"/>
                    <measurement group_id="O3" value="1.05" spread="22.3"/>
                    <measurement group_id="O4" value="0.972" spread="36.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Accumulated ratio based on AUC0-tau</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.16" spread="8.39"/>
                    <measurement group_id="O2" value="1.23" spread="6.17"/>
                    <measurement group_id="O3" value="1.16" spread="11.9"/>
                    <measurement group_id="O4" value="1.12" spread="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 8 in Urinary Glucose Excretion</title>
        <description>Change from baseline to day 8 in urinary glucose excretion. Baseline is defined as Day -2.</description>
        <time_frame>-2-0 hours(h) before drug administration and 0-2, 2-4, 4-6, 6-8, 8-12,12-16 and 16-24 h after drug administration on day -2 and day 8</time_frame>
        <population>Pharmacodynamic (PD) analysis set (PDS) contains of all patients who received study medication and have evaluable pharmacodynamic parameter data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were treated with matching placebo as tablet once daily in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 2.5 mg qd</title>
            <description>Patients were treated with 2.5 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 10 mg qd</title>
            <description>Patients were treated with 10 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Empagliflozin 25 mg qd</title>
            <description>Patients were treated with 25 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Empagliflozin 100 mg qd</title>
            <description>Patients were treated with 100 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 8 in Urinary Glucose Excretion</title>
          <description>Change from baseline to day 8 in urinary glucose excretion. Baseline is defined as Day -2.</description>
          <population>Pharmacodynamic (PD) analysis set (PDS) contains of all patients who received study medication and have evaluable pharmacodynamic parameter data.</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3254.43" spread="8250.43"/>
                    <measurement group_id="O2" value="34638.37" spread="16226.22"/>
                    <measurement group_id="O3" value="78709.87" spread="53463.52"/>
                    <measurement group_id="O4" value="74030.40" spread="35378.01"/>
                    <measurement group_id="O5" value="88040.32" spread="20265.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The mean change from baseline (day -2) to day 8 and comparisons to placebo for Urine Glucose Excretion (AE(0-24)).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0067</p_value>
            <p_value_desc>This was non-confirmatory testing.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The baseline value has been used a continuous covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>37645.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11021.57</ci_lower_limit>
            <ci_upper_limit>64269.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The mean change from baseline (day -2) to day 8 and comparisons to placebo for Urine Glucose Excretion (AE(0-24)).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>This was non-confirmatory testing.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The baseline value has been used a continuous covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>82898.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>55344.83</ci_lower_limit>
            <ci_upper_limit>110451.6</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The mean change from baseline (day -2) to day 8 and comparisons to placebo for Urine Glucose Excretion (AE(0-24)).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>This was non-confirmatory testing.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The baseline value has been used a continuous covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>79982.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>53087.22</ci_lower_limit>
            <ci_upper_limit>106878.6</ci_upper_limit>
            <estimate_desc>Mean Difference to placebo is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The mean change from baseline (day -2) to day 8 and comparisons to placebo for Urine Glucose Excretion (AE(0-24)).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>This was non-confirmatory testing.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The baseline value has been used a continuous covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>91306.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>64685.41</ci_lower_limit>
            <ci_upper_limit>117928.5</ci_upper_limit>
            <estimate_desc>Mean Difference to placebo was calculated</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Daily Glucose</title>
        <description>Change from baseline to Day 8 in mean daily glucose. Baseline is defined as Day -2.</description>
        <time_frame>0:00, 2:00, 5:00, 7:00, 10:00, 12:00,13:30 and 24:00 hours(h) after drug administration on day -2 and -0.05, 2:30, 5:00, 7:00, 10:00, 12.00, 13:30 and 24:00 hours (h) after drug administration on day 8</time_frame>
        <population>PDS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were treated with matching placebo as tablet once daily in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 2.5 mg qd</title>
            <description>Patients were treated with 2.5 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 10 mg qd</title>
            <description>Patients were treated with 10 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Empagliflozin 25 mg qd</title>
            <description>Patients were treated with 25 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Empagliflozin 100 mg qd</title>
            <description>Patients were treated with 100 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Daily Glucose</title>
          <description>Change from baseline to Day 8 in mean daily glucose. Baseline is defined as Day -2.</description>
          <population>PDS</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.85" spread="21.39"/>
                    <measurement group_id="O2" value="-27.03" spread="24.59"/>
                    <measurement group_id="O3" value="-34.04" spread="19.43"/>
                    <measurement group_id="O4" value="-25.89" spread="18.00"/>
                    <measurement group_id="O5" value="-30.96" spread="25.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The mean percent decrease in Mean daily glucose from baseline with treatment compared with placebo from baseline -2 to day 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0449</p_value>
            <p_value_desc>This was non-confirmatory testing.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The baseline value has been used a continuous covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-15.456</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-30.543</ci_lower_limit>
            <ci_upper_limit>-0.369</ci_upper_limit>
            <estimate_desc>Mean difference to placebo was calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The mean percent decrease in Mean daily glucose from baseline with treatment compared with placebo from baseline -2 to day 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0042</p_value>
            <p_value_desc>This was non-confirmatory testing.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The baseline value has been used a continuous covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-23.467</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-39.085</ci_lower_limit>
            <ci_upper_limit>-7.848</ci_upper_limit>
            <estimate_desc>Mean difference to placebo was calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The mean percent decrease in Mean daily glucose from baseline with treatment compared with placebo from baseline -2 to day 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0521</p_value>
            <p_value_desc>This was non-confirmatory testing.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The baseline value has been used a continuous covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-14.956</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-30.057</ci_lower_limit>
            <ci_upper_limit>0.145</ci_upper_limit>
            <estimate_desc>Mean difference to placebo was calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The mean percent decrease in Mean daily glucose from baseline with treatment compared with placebo from baseline -2 to day 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1676</p_value>
            <p_value_desc>This was non-confirmatory testing.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The baseline value has been used a continuous covariate.</method_desc>
            <param_type>Difference to placebo</param_type>
            <param_value>-10.602</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25.848</ci_lower_limit>
            <ci_upper_limit>4.644</ci_upper_limit>
            <estimate_desc>Mean difference to placebo was calculated</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Plasma Glucose</title>
        <description>Percentage change from baseline to Day 8 in fasting plasma glucose. Baseline is defined as Day -2.</description>
        <time_frame>-0:30 (Pre dose samples)</time_frame>
        <population>PDS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were treated with matching placebo as tablet once daily in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 2.5 mg qd</title>
            <description>Patients were treated with 2.5 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 10 mg qd</title>
            <description>Patients were treated with 10 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Empagliflozin 25 mg qd</title>
            <description>Patients were treated with 25 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Empagliflozin 100 mg qd</title>
            <description>Patients were treated with 100 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Plasma Glucose</title>
          <description>Percentage change from baseline to Day 8 in fasting plasma glucose. Baseline is defined as Day -2.</description>
          <population>PDS</population>
          <units>percentage of fasting plasma glucose</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.88" spread="12.88"/>
                    <measurement group_id="O2" value="-21.01" spread="6.38"/>
                    <measurement group_id="O3" value="-25.69" spread="9.88"/>
                    <measurement group_id="O4" value="-14.21" spread="26.00"/>
                    <measurement group_id="O5" value="-24.85" spread="8.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The mean percent change in Fasting Plasma Glucose from baseline with treatment compared with placebo from baseline -2 to day 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2239</p_value>
            <p_value_desc>This was non-confirmatory testing.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The baseline value has been used a continuous covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.269</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.162</ci_lower_limit>
            <ci_upper_limit>4.624</ci_upper_limit>
            <estimate_desc>Mean difference to placebo was calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The mean percent change in Fasting Plasma Glucose from baseline with treatment compared with placebo from baseline -2 to day 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0421</p_value>
            <p_value_desc>This was non-confirmatory testing.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The baseline value has been used a continuous covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-12.844</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-25.205</ci_lower_limit>
            <ci_upper_limit>-0.484</ci_upper_limit>
            <estimate_desc>Mean difference to placebo was calculated</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The mean percent change in Fasting Plasma Glucose from baseline with treatment compared with placebo from baseline -2 to day 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6527</p_value>
            <p_value_desc>This was non-confirmatory testing.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The baseline value has been used a continuous covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.719</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.842</ci_lower_limit>
            <ci_upper_limit>9.403</ci_upper_limit>
            <estimate_desc>Mean difference to placebo was calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The mean percent change in Fasting Plasma Glucose from baseline with treatment compared with placebo from baseline -2 to day 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1318</p_value>
            <p_value_desc>This was non-confirmatory testing.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The baseline value has been used a continuous covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-8.998</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.818</ci_lower_limit>
            <ci_upper_limit>2.822</ci_upper_limit>
            <estimate_desc>Mean difference to placebo was calculated.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Insulin</title>
        <description>Serum insulin measured for on day -2 and day 8 for AUEC0-5 and AUEC0-12. AUEC0-5: The area under the effect concentration-time curve over the time interval 0 to 5.
AUEC0-12: The area under the effect concentration-time curve over the time interval 0 to 12.</description>
        <time_frame>0.0h, 2h, 5h, 7h, 10h, 12h on day -2 &amp; day 8</time_frame>
        <population>PDS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were treated with matching placebo as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 2.5 mg qd</title>
            <description>Patients were treated with 2.5 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 10 mg qd</title>
            <description>Patients were treated with 10 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Empagliflozin 25 mg qd</title>
            <description>Patients were treated with 25 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Empagliflozin 100 mg qd</title>
            <description>Patients were treated with 100 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Insulin</title>
          <description>Serum insulin measured for on day -2 and day 8 for AUEC0-5 and AUEC0-12. AUEC0-5: The area under the effect concentration-time curve over the time interval 0 to 5.
AUEC0-12: The area under the effect concentration-time curve over the time interval 0 to 12.</description>
          <population>PDS</population>
          <units>µU*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUEC0-5 (12,9,9,9,9) on day-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134" spread="52.5"/>
                    <measurement group_id="O2" value="185" spread="79.2"/>
                    <measurement group_id="O3" value="175" spread="70.7"/>
                    <measurement group_id="O4" value="137" spread="64.7"/>
                    <measurement group_id="O5" value="119" spread="35.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUEC0-12 (12,9,9,9,9) on day-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="300" spread="111"/>
                    <measurement group_id="O2" value="474" spread="149"/>
                    <measurement group_id="O3" value="471" spread="143"/>
                    <measurement group_id="O4" value="336" spread="161"/>
                    <measurement group_id="O5" value="282" spread="41.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUEC0-5 (11,9,8,9,9) on day8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122" spread="52.0"/>
                    <measurement group_id="O2" value="174" spread="80.9"/>
                    <measurement group_id="O3" value="180" spread="74.7"/>
                    <measurement group_id="O4" value="117" spread="103"/>
                    <measurement group_id="O5" value="101" spread="37.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUEC0-12 (11,9,7,9,8) on day8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="288" spread="97.1"/>
                    <measurement group_id="O2" value="417" spread="132"/>
                    <measurement group_id="O3" value="387" spread="154"/>
                    <measurement group_id="O4" value="266" spread="193"/>
                    <measurement group_id="O5" value="275" spread="72.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Insulin</title>
        <description>Serum insulin measured for on day -2 and day 8 for Emax0-5, Emax0-12, Emin0-5 and Emin0-12.
Emax: Maximum effect (maximum measured concentration of glucose or insulin in plasma) &amp; Emin: Minimum effect (minimum measured concentration of glucose or insulin in plasma)</description>
        <time_frame>0.0h, 2h, 5h, 7h, 10h, 12h on day -2 &amp; day 8</time_frame>
        <population>PDS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were treated with matching placebo as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 2.5 mg qd</title>
            <description>Patients were treated with 2.5 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 10 mg qd</title>
            <description>Patients were treated with 10 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Empagliflozin 25 mg qd</title>
            <description>Patients were treated with 25 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Empagliflozin 100 mg qd</title>
            <description>Patients were treated with 100 mg Empagliflozin as tablet once daily (qd) in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Insulin</title>
          <description>Serum insulin measured for on day -2 and day 8 for Emax0-5, Emax0-12, Emin0-5 and Emin0-12.
Emax: Maximum effect (maximum measured concentration of glucose or insulin in plasma) &amp; Emin: Minimum effect (minimum measured concentration of glucose or insulin in plasma)</description>
          <population>PDS</population>
          <units>µU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Emax,0-5 (12,9,9,9,9) on day-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.1" spread="17.3"/>
                    <measurement group_id="O2" value="55.2" spread="29.9"/>
                    <measurement group_id="O3" value="51.2" spread="23.4"/>
                    <measurement group_id="O4" value="40.2" spread="19.4"/>
                    <measurement group_id="O5" value="35.2" spread="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emax,0-12 (12,9,9,9,9) on day-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.4" spread="12.6"/>
                    <measurement group_id="O2" value="68.5" spread="25.3"/>
                    <measurement group_id="O3" value="72.1" spread="27.7"/>
                    <measurement group_id="O4" value="48.7" spread="30.9"/>
                    <measurement group_id="O5" value="45.3" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emin,0-5 (12,9,9,9,9) on day-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" spread="5.46"/>
                    <measurement group_id="O2" value="14.1" spread="5.45"/>
                    <measurement group_id="O3" value="13.7" spread="4.62"/>
                    <measurement group_id="O4" value="9.16" spread="7.59"/>
                    <measurement group_id="O5" value="7.86" spread="2.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emin,0-12 (12,9,9,9,9) on day-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.98" spread="4.86"/>
                    <measurement group_id="O2" value="14.1" spread="5.45"/>
                    <measurement group_id="O3" value="13.5" spread="4.37"/>
                    <measurement group_id="O4" value="9.16" spread="7.59"/>
                    <measurement group_id="O5" value="7.86" spread="2.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emax,0-5 (11,9,8,9,9) on day8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.6" spread="15.6"/>
                    <measurement group_id="O2" value="56.0" spread="32.1"/>
                    <measurement group_id="O3" value="56.3" spread="25.4"/>
                    <measurement group_id="O4" value="36.2" spread="37.3"/>
                    <measurement group_id="O5" value="29.6" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emax,0-12 (11,9,8,9,9) on day8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.6" spread="13.1"/>
                    <measurement group_id="O2" value="70.2" spread="26.1"/>
                    <measurement group_id="O3" value="68.6" spread="31.1"/>
                    <measurement group_id="O4" value="44.4" spread="35.5"/>
                    <measurement group_id="O5" value="37.3" spread="8.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emin,0-5 (11,9,8,9,9) on day8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.55" spread="3.82"/>
                    <measurement group_id="O2" value="8.63" spread="3.39"/>
                    <measurement group_id="O3" value="10.7" spread="5.60"/>
                    <measurement group_id="O4" value="5.33" spread="3.14"/>
                    <measurement group_id="O5" value="3.96" spread="2.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emin,0-12 (11,9,8,9,9) on day8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.41" spread="3.90"/>
                    <measurement group_id="O2" value="8.53" spread="3.46"/>
                    <measurement group_id="O3" value="10.7" spread="5.60"/>
                    <measurement group_id="O4" value="5.17" spread="3.19"/>
                    <measurement group_id="O5" value="3.96" spread="2.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>day1 to day21</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Patients were treated with matching placebo as tablet once daily in the morning.</description>
        </group>
        <group group_id="E2">
          <title>Empagliflozin 2.5 mg qd</title>
          <description>Patients were treated with 2.5 mg Empagliflozin as tablet once daily in the morning.</description>
        </group>
        <group group_id="E3">
          <title>Empagliflozin 10 mg qd</title>
          <description>Patients were treated with 10 mg Empagliflozin as tablet once daily in the morning.</description>
        </group>
        <group group_id="E4">
          <title>Empagliflozin 25 mg qd</title>
          <description>Patients were treated with 25 mg Empagliflozin as tablet once daily in the morning.</description>
        </group>
        <group group_id="E5">
          <title>Empagliflozin 100 mg qd</title>
          <description>Patients were treated with 100 mg Empagliflozin as tablet once daily in the morning.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 10.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Gastric disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

